Additional clinical outcomes. (A) Patient-reported outcomes (Lee cGVHD Symptom Scale). The skin, muscle, and total symptom scores for patients at all dose levels are shown at baseline (W0, gray) and at weeks 8 to 12 (W8-12, red). For weeks 8 to 12, the scores for weeks 8, 10, and 12 were combined and the average score was used for patients who had measurements at those timepoints. Bar graphs represent median values. Whiskers represent the interquartile range. (B) OS. (C) Steroid dose reduction by response group at week 12. Each bar represents an individual patient. The 1 patient with SD at week 8, who had 50% steroid dose reduction at week 12, achieved PR during the extension period. SD/MR, stable disease with minor response (blue); SD/MR/PD, stable disease, mixed response, progressive disease (green).